

20 March 2024 EMA/HMPC/320292/2023 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Eucalyptus globulus* Labill.; *Eucalyptus polybractea* R.T. Baker; *Eucalyptus smithii* R.T. Baker, aetheroleum

Draft - Revision 1

Initial assessment	
Discussion in Working Party on European Union monographs and	May 2012
European Union list (MLWP)	September 2012
	November 2012
	March 2013
Adopted by Committee on Herbal Medicinal Products (HMPC) for	14 May 2013
release for consultation	14 May 2013
End of consultation (deadline for comments)	15 November 2013
Rediscussion in MLWP	January 2014
Adoption by HMPC	
Monograph (EMA/HMPC/307781/2012)	
Assessment Report (EMA/HMPC/307782/2012)	
List of References (EMA/HMPC/307783/2012)	25 March 2014
Overview of Comments received during the public consultation	
(EMA/HMPC/32373/2014)	
HMPC Opinion (EMA/HMPC/283230/2014)	
First systematic review	
Discussion in MLWP	July 2023
	January 2024 March 2024
	March 2024
Adopted by HMPC for release for consultation	20 March 2024
Start of public consultation	15 April 2024
End of consultation (deadline for comments). Comments should be provided using this <u>template</u> to <u>hmpc.secretariat@ema.europa.eu</u>	15 July 2024

Keywords	Committee on Herbal Medicinal Products; HMPC; European Union herbal
	monographs; herbal medicinal products; traditional use; Eucalyptus globulus
	Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker,
	aetheroleum; Eucalypti aetheroleum; Eucalyptus oil

 Official address
 Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

 Address for visits and deliveries
 Refer to www.ema.europa.eu/how-to-find-us

 Send us a question
 Go to www.ema.europa.eu/contact

 Telephone +31 (0)88 781 6000
 An agency of the European Union



 \odot European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.

BG (bălgarski): Евкалиптово масло	LT (lietuvių kalba): Eukaliptų eterinis aliejus
CS (čeština): blahovičníková silice	LV (latviešu valoda): Eikalipta ēteriskā eļļa
DA (dansk): Eucalyptusolie	MT (malti): Żejt tal-Ewkaliptus
DE (Deutsch): Eukalyptusöl	NL (nederlands): Eucalyptusolie
EL (elliniká): αιθέριο έλαιο ευκαλύπτου	PL (polski): Olejek eteryczny eukaliptusowy
EN (English): Eucalyptus oil	PT (português): Óleo essencial de eucalipto
ES (espanol): Eucalipto, aceite esentcial de	RO (română): ueli volatil de eucalipt
ET (eesti keel): eukalüptiõli	SK (slovenčina): Eukalyptovà silica
FI (suomi): eukalyptusöljy	SL (slovenščina): eterično olje evkalipta
FR (français): Eucalyptus (huile essentielle d')	SV (svenska): Eukalyptusolja
HU (magyar): Eukaliptuszolaj	IS (íslenska):
HR (hrvatska): Eukaliptusovo eterično ulje	NO (norsk): Eukalyptusolje
IT (italiano): Eucalipto essenza	

European Union herbal monograph on *Eucalyptus globulus* Labill.; *Eucalyptus polybractea* R.T. Baker; *Eucalyptus smithii* R.T. Baker, aetheroleum

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC
	<i>Eucalyptus globulus</i> Labill.; <i>Eucalyptus polybractea</i> R.T. Baker; <i>Eucalyptus smithii</i> R.T. Baker, aetheroleum (Eucalyptus oil)
	i) Herbal substance Not applicable
	ii) Herbal preparations Essential oil

3. Pharmaceutical form

Well-established use	Traditional use
	Herbal preparations in solid dosage forms for oral use.
	Herbal preparations in liquid dosage forms for inhalation, cutaneous use and bath additive.
	Herbal preparations in semi-solid dosage forms for cutaneous use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

 $^{^1}$ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

² The material complies with the Ph. Eur. monograph (ref.: 07/2021:0390)

European Union herbal monograph on *Eucalyptus globulus* Labill.; *Eucalyptus polybractea* R.T. Baker; *Eucalyptus smithii* R.T. Baker, aetheroleum EMA/HMPC/320292/2023

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product used for relief of cough associated with cold.
	Indication 2)
	Traditional herbal medicinal product used for the symptomatic relief of localised muscle pain.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Indication 1)
	<u>Oral use</u> Adolescents, adults and elderly
	Single dose: 100-200 mg, 2-5 times daily Daily dose: 200-600 mg
	The use in children under 24 months of age is contraindicated (see section 4.3 'Contraindication'). The use in children between 2 and 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	<u>Cutaneous use</u> liquid dosage forms (pure eucalyptus oil)
	<i>Children from 3 years of age, adolescents, adults and elderly</i>
	Single dose: rub a few drops on chest and back, 2-3 times daily
	 semi-solid dosage forms (10% eucalyptus oil)
	Adolescents, adults and elderly and children between 3 and 12 years of age

Well-established use	Traditional use
	Single dose: apply a thin layer on chest and back, 2-3 times daily
	The use in children under 24 months of age is contraindicated (see section 4.3 'Contraindication'). The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Inhalation liquid dosage forms (pure eucalyptus oil)
	Adolescents, adults and elderly
	Single dose: 3-8 drops per 250 ml boiling water, 3 times daily
	Children between 3 and 11 years of age
	Single dose: up to 2-4 drops per 250 ml boiling water, 3 times daily.
	The use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications'). The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Bath additive • liquid dosage forms
	Adolescents, adults and elderly Single dose: 1.5-6 g essential oil/100 l water, 3 to 4 times a week
	Children between 3 and 11 years of age Single dose: 0.5-3 g essential oil/100 l water, 3 to 4 times a week
	Recommended bath temperature is 35-38°C, 10-20 min
	The use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications'). The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').

Indication 2)Cutaneous use• liquid dosage forms (pure eucalyptus oil)Adolescents, adults and elderly and children between 3 and 12 years of ageSingle dose: rub a few drops on the skin of the affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10% eucalyptus oil)Adolescents, adults and elderly and children between 3 and 12 years of ageSingle dose: rub a few drops on the skin of the affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10% eucalyptus oil)Adolescents, adults and elderly and children between 3 and 12 years of ageSingle dose: apply a thin layer on the affected area, 2 to 3 times dailyThe use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications').The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').Bath additive • liquid dosage forms
 liquid dosage forms (pure eucalyptus oil) Adolescents, adults and elderly and children between 3 and 12 years of age Single dose: rub a few drops on the skin of the affected area, 2-3 times daily in semi-solid dosage forms (ointments 10% eucalyptus oil) Adolescents, adults and elderly and children between 3 and 12 years of age Single dose: apply a thin layer on the affected area, 2 to 3 times daily The use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications'). The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Bath additive liquid dosage forms
Adolescents, adults and elderly and children between 3 and 12 years of ageSingle dose: rub a few drops on the skin of the affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10% eucalyptus oil)Adolescents, adults and elderly and children between 3 and 12 years of ageSingle dose: apply a thin layer on the affected area, 2 to 3 times dailyThe use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications').The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').Bath additive • liquid dosage forms
between 3 and 12 years of ageSingle dose: rub a few drops on the skin of the affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10% eucalyptus oil)Adolescents, adults and elderly and children between 3 and 12 years of ageSingle dose: apply a thin layer on the affected area, 2 to 3 times dailyThe use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications').The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').Bath additive • liquid dosage forms
affected area, 2-3 times daily• in semi-solid dosage forms (ointments 10% eucalyptus oil)Adolescents, adults and elderly and children between 3 and 12 years of ageSingle dose: apply a thin layer on the affected area, 2 to 3 times dailyThe use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications').The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').Bath additive • liquid dosage forms
eucalyptus oil)Adolescents, adults and elderly and children between 3 and 12 years of ageSingle dose: apply a thin layer on the affected area, 2 to 3 times dailyThe use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications').The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').Bath additive • liquid dosage forms
between 3 and 12 years of ageSingle dose: apply a thin layer on the affected area, 2 to 3 times dailyThe use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications'). The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').Bath additive • liquid dosage forms
area, 2 to 3 times dailyThe use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications').The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').Bath additive • liquid dosage forms
contraindicated (see section 4.3 'Contraindications'). The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). <u>Bath additive</u> • liquid dosage forms
liquid dosage forms
Adolescents, adults and elderly
Single dose: 2.7-4 g essential oil/100 l water, 3 to 4 times a week
Children between 3 and 12 years of age
Single dose: 0.5-3 g essential oil/100 l water, 3 to 4 times a week
Recommended bath temperature is 35-38°C, 10-20 min
The use in children under 24 months of age is contraindicated (see section 4.3 'Contraindications'). The use in children between 2 and 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
Duration of use
Duration of use

Well-established use	Traditional use
	Indication 1)
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Indication 2)
	<u>Cutaneous use</u> If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Use as bath additive If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use (indication 1)
	Inhalation (indication 1)
	Cutaneous use (indication 1 and 2)
	Use as bath additive (indication 1 and 2)

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to eucalyptus oil or 1,8-cineol.
	Children with history of seizures (febrile or not).
	Children under 24 months of age, because there is a risk that 1,8-cineole containing preparations, like other essential oils, can induce laryngospasm.
	Full hot baths are contraindicated in cases of large skin injuries and open wounds, acute skin diseases, high fever, severe infections, severe circulatory disturbances and cardiac failure.

Well-established use	Traditional use
	Indication 1
	When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted.
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	<u>Oral use</u> The use in children under 12 years of age has not been established due to lack of adequate data.
	Eucalyptus oil should be used with caution in in inflamed and ulcerated conditions of the gastrointestinal tract.
	<u>Inhalation</u> The use in children under 3 years of age has not been established due to lack of adequate data.
	Caution is necessary in inhalations with hot water, to avoid burns. The area of the eyes should be outside of the steam.
	<u>Cutaneous use and use as bath additive</u> The use in children between 2 and 3 years of age has not been established due to lack of adequate data.
	Eye contact with unwashed hands after the application may potentially cause irritation.
	Eucalyptus oil should not be applied on broken or irritated skin.
	Indication 2
	When reddening or swelling of the aching parts occur a doctor or a qualified health care practitioner should be consulted.
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children between 2 and 3 years of age has not been established due to lack of adequate data.
	Eye contact with unwashed hands after the application may potentially cause irritation.
	Eucalyptus oil should not be applied on broken or irritated skin.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data are available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	<u>All uses:</u> Immune system disorders allergic reactions including severe allergic reactions as systemic allergic reactions
	<u>Oral use:</u> Gastrointestinal disorders gastrointestinal reactions (as heart burn, abdominal pain, nausea, vomiting, diarrhoea)
	Cutaneous use: skin and subcutaneous tissue disorders

Well-established use	Traditional use
	contact eczema The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care
	practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	Intake of doses larger than those recommended can provoke gastro-intestinal symptoms (such as abdominal pain, vomiting, diarrhoea, nausea); respiratory problems; central nervous problems (such as CNS depression, loss of consciousness, convulsions, ataxia), constricted pupils.
	Accidental overdose of liniments or bath preparations may cause skin irritation.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC, unless necessary for the safe use of the product.

Well-established use	Traditional use
	Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

20 March 2024